23 January 2020
Visiongain’s new report the Ovarian Cancer Drugs Market Report 2020-2030: Forecasts by Therapeutic Class(PARP, PD-L1, Angiogenesis Inhibitors) plus analysis of leading companies indicates that the global Ovarian Cancer Drugs market will grow at a CAGR over 20.0% by 2030.
One of the main factors in accelerating market growth is the rising incidence of ovarian cancer due to growing geriatric population and unhealthy lifestyles. In addition to this, it is projected that rising acceptance of new drugs and the existence of a large clinical pipeline would greatly improve the demand for treating ovarian cancer. Ovarian cancer is the seventh most common cancer among women worldwide and causes more deaths each year than any other gynecological disease, according to the World Cancer Research Fund International (WCRF). About 235,200 new cases and 140,000 deaths worldwide were recorded in 2016. For older women with a peak age of 63 years, this condition primarily occurs.
Mortality rates have fallen globally over the past decade and are expected to continue to decrease over the forecast period in the U.S., Europe and to a lesser degree in Japan. Increasing contraceptive use and rising hormone therapy use result in lower mortality rates as a result of this cancer. Ovarian cancer is the tenth most common cancer among women in the U.S., according to the Centers for Disease Control and Prevention (CDC), and is the deadliest of all gynecological malignancies, causing more than 14,000 deaths annually. In 2017, there were 22,440 diagnoses of ovarian cancer and 14,080 deaths in the U.S. PARP inhibitors are likely to contribute to the majority of market share in 2022 among the major drug groups, backed by sustained use of approved drugs and superior efficacy. It is also expected that the adoption of checkpoint inhibitors would support market growth. Before 2014, the options available for treating ovarian cancer included mainly chemotherapy, radiation, and surgery, and generics dominated the marketplace. With the introduction of PARP inhibitors and angiogenesis inhibitors, the ovarian cancer care landscape has changed dramatically over the past few years. As highly promising economies, China and India present tremendous growth prospects for expansion of the market.
Factors such as increased incidence of ovarian cancer, favorable health care reforms, increased health education, low cost base, and lack of regulatory and cultural inhibitions are the primary catalyst for growth for the Indian and Chinese industry. AstraZeneca, Roche, Tesaro, and Clovis Oncology are some of the key players operating on the market. The expiration of patents and increased competition from PARP inhibitors are likely to affect the market share of Avastin. In the second-line platinum-sensitive environment, Roche's combination therapy based on Tecentriq is expected to gain popularity as the preferred treatment choice. For advanced stage patients with BRCA mutations, PARP inhibitors are likely to become the preferred maintenance therapy choice.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The 431-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market.
03 July 2020
Where is the Clinical Workflow Solutions market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.
03 July 2020
With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low.
01 July 2020
The market growth is attributed to the growing adoption of big data and AI in data management and monitoring of clinical information in health care.